FOC5-4HEPATITIS C TREATMENT WITH NEW ORAL COMBINAISONS IN THE ADDICTION CARE SETTING

Abstract

Background. Hepatitis C virus (HCV) infection is highly prevalent in patients suffering from an addiction. Although the feasibility of interferon-based has been demonstrated in this population, access to HCV treatment remains reduced in addicted patients and there are very few data on the use new "interferon-free" oral combinations in that setting. Methods. patients infected with HCV and advanced fibrosis (de-monstrated by non-invasive test) followed in four addictions care centres were considered for a treatment combining sofosbuvir and an NS5A inhibitor (daclatasvir or ledipasvir) during 12 weeks (24 weeks for cirrhotic patients with genotype 3). A multidisciplinary team including addiction specialists, hepatologists and pharmacist reviewed all indications and decided the practical implementation of the treatments. Results. Treatment has been introduced to date in 33 patients (M/F 28/5). All patients received a substitution for opioid dependence and 26/33 (78%) had also an alcohol use disorder. Most patients suffered from some forms of psychosocial vulnerability. In all case, HCV RNA became undetectable during treatment. 14 patients have completed their treatment and no virological relapse has been reported to date. Sustained virological response has been established in 11. Actualised results will be presented at the congress. Conclusion. Our preliminary results suggest that the use of new oral combinations for the treatment of HCV infection could be highly ef-fective in addiction care settings.